Why Lean Clinical Teams Often Create Fragile Clinical Supply Chains

By Suzanne Vyvoda, founder and principal, Concordia BioStrategies

Clinical supply is rarely the headline risk in early development planning. Scientific differentiation, regulatory strategy, site selection, and financing milestones appropriately dominate attention. Manufacturing is contracted. Distribution pathways are scoped. Depot networks are selected.

On paper, supply appears covered. Yet as programs scale, clinical supply is frequently the function that introduces avoidable delays and cost variability.

In many emerging and midsize biotech organizations, supply governance is not intentionally designed. It evolves. CMC oversees batch release and packaging. Clinical operations manages enrollment pacing and site activation. CRO partners coordinate depots and distribution. CDMOs execute shipments once product is released.

Each function operates within defined scope. What is less frequently defined is who owns the ongoing alignment between enrollment, inventory positioning, and shipment execution.

In large pharmaceutical organizations, that integration layer is institutionalized. Forecast reconciliation, inventory positioning, and global shipment oversight sit within a formal supply organization. In lean sponsor environments, that structure is often implicit rather than explicit. The expectation is that experienced partners working together will create cohesion.

That expectation is reasonable. It is also where fragility can begin.

How Supply Friction Quietly Emerges In Global Programs

Consider a midsize sponsor running a Phase 2 study across the United States, Western Europe, and Eastern Europe. Enrollment proves uneven. Several Western European sites underperform relative to forecast, while investigators in Eastern Europe accelerate unexpectedly.

Drug product and comparator inventory were positioned based on earlier projections. Forecast reconciliation occurs monthly, often in static slide decks that lag behind live enrollment data. Shipment visibility is distributed across carrier portals and depot systems.

Within weeks, high-enrolling sites approach local inventory thresholds. Comparator resupply requires expedited repositioning. A shipment destined for a high-performing region is delayed at customs pending documentation clarification. By the time escalation reaches the sponsor, multiple patient visits have been rescheduled.

No single vendor failed. Each acted within defined scope. The issue was not effort. It was the absence of real-time alignment between enrollment velocity and supply positioning.

In competitive therapeutic areas where enrollment pools are limited and multiple programs compete for the same sites, lost momentum is difficult to regain. Supply disruptions are rarely dramatic. They compound quietly.

Distributed Responsibility, Undefined Accountability

Clinical supply instability does not necessarily reflect poor execution. In many organizations, data exists. Inventory reports are generated. Shipment logs are reviewed. Forecasts are updated. The issue is often fragmented visibility combined with diffuse ownership.

In lean sponsor environments, supply synchronization frequently sits between functions. CMC monitors release schedules. Clinical operations tracks enrollment. The CRO manages depot operations. Couriers provide shipment updates through separate systems.

Each group fulfills its responsibilities. What is less consistently defined is who owns the integrated, real-time view.

Shipment data may exist but remain fragmented across carrier portals, depot platforms, spreadsheets, and email threads. Temperature monitoring information may be available but reviewed retrospectively. Customs documentation status may not be visible until a delay has already occurred. Enrollment velocity may shift more rapidly than forecast refresh cycles.

In practice, these issues rarely appear in early risk assessments. They surface mid-execution, when corrective flexibility is lowest. When constraints emerge, the operational dynamic is familiar. A site reports missing kits. Enrollment is at risk. A cross-functional meeting is convened. Clinical operations, CMC, the CRO, and sometimes quality review available data.

The central question arises: who is accountable for resolving this before it affects additional patients? In smaller organizations, the answer is sometimes silence rather than clarity. Responsibility may have been distributed. Visibility may have been partial. That gap becomes operationally expensive as programs scale.

Program Complexity Often Outpaces Supply Oversight

Early-phase, single-region studies can tolerate informal coordination. Global Phase 2 and 3 programs cannot. Multi-country development introduces compounding variables:

• Country-specific import regulations
• Local labeling and relabeling requirements
• Temperature-controlled shipment monitoring
• Comparator procurement and resupply logistics
• Ancillary kit coordination
• Variable enrollment rates across geographies

Each variable increases the need for active reconciliation between enrollment data and supply positioning.

Supply instability rarely presents as catastrophic failure. It shows up in small but cumulative events:

• A shipment arrives later than anticipated.
• A comparator supply requires expedited courier support.
• A temperature excursion triggers investigation.
• A site reschedules a patient visit.

Over time, these events influence enrollment pacing, cost predictability, and stakeholder confidence.

The Hidden Cost Of Supply Variability

The financial impact of supply fragility rarely appears in a single line item.

Expedited international shipments, emergency relabeling, supplemental depot transfers, and compressed comparator procurement introduce incremental cost. Across a global program, these adjustments accumulate.

The time impact is often more significant.

In global studies enrolling hundreds of patients across dozens of sites, visit rescheduling across even a modest percentage of sites can extend enrollment timelines by several weeks. In milestone-driven development models, weeks influence database lock timing, regulatory sequencing, and financing expectations.

Financial projections assume operational stability. When supply coordination is reactive rather than proactive, forecast precision declines.

Patients experience this instability directly. Individuals managing chronic or progressive disease cannot be casually rescheduled without consequence. Supply reliability shapes the trial experience as much as protocol design.

When Supply Constraints Are Misdiagnosed

When enrollment slows, attention frequently shifts to feasibility assumptions or site performance. In geographically diverse programs, acceleration in one region and underperformance in another may obscure the role of supply alignment. If inventory positioning lags behind enrollment velocity, friction emerges operationally but may be misclassified as site inefficiency rather than coordination failure.

Without integrated visibility linking enrollment data, inventory thresholds, shipment tracking, and deviation alerts, root causes are easily misinterpreted. By the time supply constraints are recognized as systemic rather than situational, corrective measures become reactive and more costly.

Reframing clinical supply as an accountable operating function rather than a downstream logistics activity changes how organizations interpret and address risk.

Why Real-Time Visibility Is Becoming Essential

The growth of real-time logistics orchestration platforms reflects recognition that fragmented shipment visibility is incompatible with modern global development. Historically, shipment tracking has resided across multiple carrier portals, depot systems, spreadsheets, and email threads. Temperature data and customs documentation have often been reviewed separately. Intervention occurs after deviation rather than at its onset.

Integrated logistics platforms consolidate tracking across carriers, automate deviation alerts, integrate temperature monitoring data, and provide shared dashboards accessible to sponsor and CRO stakeholders.

For lean sponsor teams without dedicated supply departments, this infrastructure strengthens oversight. It enables earlier detection of customs delays, tighter reconciliation between enrollment velocity and inventory positioning, and more predictable execution.

Technology does not replace accountability. It supports it.

Designing Governance Before First Patient In

Sponsors can reduce supply fragility through structural clarity early in development:

• Designate a single accountable owner for end-to-end supply coordination across CMC, clinical operations, and external partners.
• Increase forecast reconciliation cadence in therapeutic areas where enrollment velocity may shift rapidly.
• Define escalation triggers tied to regional inventory thresholds.
• Consolidate shipment visibility across carriers and depots rather than relying on fragmented portals.
• Integrate comparator and ancillary kit planning directly into core enrollment forecasting processes.

These measures do not require significant headcount expansion. They require deliberate ownership and oversight.

From Logistics Function To Core Operating Discipline

Clinical supply has traditionally been positioned as operational logistics. In complex global development programs, it directly shapes execution.

Supply oversight influences enrollment reliability, cost predictability, patient experience, and capital planning precision. Lean operating models are not inherently fragile. Fragility emerges when integration responsibilities are assumed rather than clearly assigned.

As development timelines compress and financial scrutiny intensifies, reducing operational variability carries measurable value. Sponsors that treat supply coordination as a core operating discipline rather than administrative support are better positioned to scale without introducing avoidable volatility.

About The Author:

Suzanne Vyvoda is a clinical research and operations executive with more than 20 years of experience across the clinical trial ecosystem, including research sites, CROs, and global biotech and pharmaceutical organizations. She is the founder of Concordia BioStrategies, where she advises clinical-stage biotech companies, technology platforms, and investors on clinical trial strategy, operational leadership, and execution.